R^7 and R^8 are independently selected from the group consisting of hydrogen, optionally substituted C_{1-6}alkyl and optionally substituted C_{3-7}cycloalkyl; and

X is CH_2, oxygen, sulfur or SO_2.

[0026a] In a first aspect, there is provided a compound of formula II:



Formula II

or a pharmaceutically acceptable salt, solvate, or polymorphic form thereof; wherein:

R^5 is an unsubstituted phenylene group or a phenylene group substituted by one or more groups independently selected from alkyl, halo, alkoxy and haloalkyl;

R^6 is selected from



R^7 and R^8 are independently selected from the group consisting of hydrogen, optionally substituted C_{1-6}alkyl and optionally substituted C_{3-7}cycloalkyl; and

X is oxygen;

wherein the term "alkyl" refers to monovalent straight chain or branched chain saturated hydrocarbon radicals having from 1 to 6 carbon atoms, and

wherein the term “halo” refers to fluorine, chlorine, bromine and iodine, and

wherein the term "alkoxy" refers to straight chain or branched alkyloxy groups, wherein alkyl is as defined above, and

wherein the term "optionally substituted" means the group to which this term refers may be unsubstituted, or may be substituted with one or more groups independently selected from halogen, C_1-C_6alkyl, C_2-C_6alkenyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, hydroxy(C_{1-6})alkyl, C_3-C_6cycloalkyl, C(O)H, C(O)OH, NHC(O)H, NHC(O)C_1-C_4alkyl, C(O)C_1-C_4alkyl, NH_2, NHC_1-C_4alkyl, N(C_1-C_4alkyl)$_2$, NO_2, OH and CN.

[0026b] In a second aspect, there is provided a pharmaceutically acceptable salt of a compound as disclosed herein. In a third aspect, there is provided the pharmaceutically acceptable salt (*E*)-4-(2-(Aminomethyl)-3-fluoroallyloxy)-*N*-*tert*-butylbenzamide hydrochloride.

[0027] In a fourth aspect, there is provided a composition comprising a compound as disclosed herein, or a pharmaceutically acceptable salt as disclosed herein or a solvate thereof, and at least one pharmaceutically acceptable excipient, carrier or diluent.

[0027a] In a fifth aspect, there is provided use of a compound as disclosed herein, or a pharmaceutically acceptable salt as disclosed herein or a solvate thereof, in the manufacture of a medicament for treating a disease associated with or modulated by SSAO/VAP-1 protein, wherein the disease is inflammation, fibrosis, Type I diabetes and complications thereof, Type II diabetes and complications thereof, a diabetes-induced disease, a neuroinflammatory disease or cancer.

[0028] In one embodiment, there is provided a method of inhibiting the amine oxidase activity of SSAO/VAP-1 in a subject in need thereof, said method comprising administering to said subject an effective amount of a compound as disclosed herein, or a pharmaceutically acceptable salt or solvate thereof, or a composition as disclosed herein.

[0029] In one embodiment, there is provided a method of treating a disease associated with or modulated by SSAO/VAP-1 protein, said method comprising administering to a subject in need thereof a therapeutically effective amount of a compound as disclosed herein, or a pharmaceutically acceptable salt or solvate thereof, or a composition as disclosed herein.

[0030] In one embodiment , there is provided a method of treating a disease associated with or modulated by SSAO/VAP-1, said method comprising administering to a subject in need thereof a therapeutically effective amount of a compound as disclosed herein, or a pharmaceutically acceptable salt or solvate thereof, or a composition as disclosed herein.

Claims:

1. A compound of Formula II:



Formula II

or a pharmaceutically acceptable salt, solvate, or polymorphic form thereof; wherein:

R^5 is an unsubstituted phenylene group or a phenylene group substituted by one or more groups independently selected from alkyl, halo, alkoxy and haloalkyl;

R^6 is selected from



R^7 and R^8 are independently selected from the group consisting of hydrogen, optionally substituted C_{1-6}alkyl and optionally substituted C_{3-7}cycloalkyl; and

X is oxygen;

wherein the term "alkyl" refers to monovalent straight chain or branched chain saturated hydrocarbon radicals having from 1 to 6 carbon atoms, and

wherein the term “halo” refers to fluorine, chlorine, bromine and iodine, and

wherein the term "alkoxy" refers to straight chain or branched alkyloxy groups, wherein alkyl is as defined above, and

wherein the term "optionally substituted" means the group to which this term refers may be unsubstituted, or may be substituted with one or more groups independently selected from halogen, C_1-C_6alkyl, C_2-C_6alkenyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, hydroxy(C_{1-6})alkyl, C_3-C_6cycloalkyl, C(O)H, C(O)OH, NHC(O)H, NHC(O)C_1-C_4alkyl, C(O)C_1-C_4alkyl, NH_2, NHC_1-C_4alkyl, N(C_1-C_4alkyl)$_2$, NO_2, OH and CN.

2. A compound of Claim 1, wherein R^5 is an unsubstituted phenylene group or a phenylene group substituted by one or more groups independently selected from methyl, fluorine, chlorine, bromine, OCH_3 and CF_3.

3. A compound of Claim 1 or 2 wherein R^7 and R^8 are independently selected from the group consisting of hydrogen and $C_{1\text{-}6}$alkyl.

4. A compound of any one of Claims 1 to 3 wherein R^6 is  wherein R^7 and R^8 are defined as in claim 1 or 3.

5. A compound of any one of Claims 1 to 3 wherein R^6 is  wherein R^7 and R^8 are defined as in claim 1 or 3.

6. A compound of Claim 1 wherein said compound is selected from the group consisting of: